the percentages are just for price risking - how much do discount the value that product brings to the share price. They have done this accurately in their guidance.
I agree with BP on most of this stuff (except possibly the price target). I think success at the type A meeting is likely to be inhibited by the FDA's clear need for an MSC RCT, we should see scenario 2 or 3 from their report.
Covid breaks the ice for approval on the other products because it is a full RCT and the FDA wants therapies to be approved so they have tools to fight the pandemic. Q4 and Q1 2021 there's going to be a few new therapies for covid approved, I think. Ours will be just one, but it's big for MSB and future products!
if the price tanks after the type A meeting I'll buy a trading parcel.
Updated Broker Report: Bel Potter, page-15
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.025(2.70%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 94.0¢ | 96.8¢ | 93.5¢ | $4.207M | 4.417M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 42268 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.0¢ | 48002 | 3 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |